Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.

Beckman, Joan D; Rollins-Raval, Marian A; Raval, Jay S; Park, Yara A; Mazepa, Marshall; Ma, Alice

Beckman, Joan D; Rollins-Raval, Marian A; Raval, Jay S; Park, Yara A; Mazepa, Marshall; Ma, Alice.

Afiliación

Beckman JD; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC.
Rollins-Raval MA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
Raval JS; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
Park YA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
Mazepa M; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
Ma A; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC.

Am J Ther ; 25(2): e270-e272, 2018.

Article en En | MEDLINE | ID: mdl-29293474

Asunto(s)

Bortezomib/uso terapéutico; Inhibidores de Proteasoma/uso terapéutico; Púrpura Trombocitopénica Idiopática/tratamiento farmacológico; Femenino; Humanos; Factores Inmunológicos/uso terapéutico; Persona de Mediana Edad; Receptores de Trombopoyetina/agonistas; Recurrencia; Resultado del Tratamiento

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Púrpura Trombocitopénica Idiopática / Inhibidores de Proteasoma / Bortezomib Límite: Female / Humans / Middle aged Idioma: En Revista: Am J Ther Asunto de la revista: TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Nueva Caledonia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google